Featured Video


A Mark of Success?
Achim Schneeberger, MD, talks about the Phase II study that demonstrated…



HDBuzzCast: Creatine and coenzyme Q10, trials that finish early, supplements, and getting involved http://t.co/EkTTqCwvs5



Acorda Therapeutics to Acquire Civitas Therapeutics

Acorda Therapeutics has entered into an agreement to acquire privately-held biopharmaceutical company Civitas Therapeutics for $525 million in cash. Acorda will obtain worl…

Therapeutic Update

FDA APPROVES MOVANTIK FOR OPIOIDINDUCED CONSTIPATION FDA approved Movantik (naloxegol, Astra-Zeneca), an oral treatment for opioid-induced constipation in adults with chro…

Migraine in Middle Age Linked to Increased Risk of PD, Movement Disorders Later

People who experience migraine in middle age may be more likely to develop Parkinson’s disease, or other movement disorders later in life, a new study suggests. Those who…

Plegridy Two-Year Data Confirm Maintenance of Efficacy and Safety

Biogen presented new data from the second year of its Phase III ADVANCE clinical trial that show the positive treatment effects of Plegridy (peginterferon beta-1a) were main…

Featured NeuroTopic


Movement Disorders


Contact Info

For advertising rates and opportunities:
Steve Farrell

For further information:
Alan Guralnick
Group Publisher
(484) 581-1832

About Practical Neurology

Launched in January 2002, Practical Neurology strives to enhance quality of care and improve the daily operation of neurology practices. Each month, our experts explain the real-world significance of recent advances in neurologic science and offer step-by-step advice on how to overcome the clinical and business challenges neurologists face. Our straightforward, how-to articles give neurologists tools they can put into practice right away.

Website Design by Sides Media